Rao Deepak, Shah Saumya
Department of Surgical Oncology (Head and Neck Services), The Gujarat Cancer Research Institute (GCRI), Civil Hospital Campus, Asarva, Ahmedabad, Gujarat 380006 India.
Indian J Otolaryngol Head Neck Surg. 2019 Oct;71(Suppl 1):447-452. doi: 10.1007/s12070-018-1347-y. Epub 2018 Apr 16.
Head and neck cancers are one of the commonest malignancies in India. Majority of cases of head and neck malignancy undergo chemoradiation with or without surgery. Thyroid bears the brunt in terms of either excision or the gland tends to get irradiated and fibrosed. In either scenario the functionality of gland is lost leading to hypothyroidism and other clinical manifestations. It tends to get subclinical and goes unnoticed. To identify the occurrence of clinical and subclinical hypothyroidism among head and neck cancer patients receiving radiation to the neck and to justify routine use of thyroid function tests during follow up. It was a prospective non randomized control study of 100 patients of head and neck cancer receiving radiotherapy for duration of 1 year. Thyroid stimulating hormone and T3 and T4 estimations were done at baseline and at 3 and 9 months following radiotherapy. Out of 100 patients, 72 (72%) were males and 28 (28%) were females. All the patients received radiation to the neck to a dose of > 30 Gy. 35 patients received concurrent chemotherapy. 11 patients were found to have subclinical hypothyroidism while 32 patients developed significant clinical hypothyroidism ( value of 0.001). Thus a total of 43 patients developed radiation induced hypothyroidism. 20 of the 32 patients who developed clinical hypothyroidism were in the age group of 41-50 years. 11 of 32 patients who developed clinical hypothyroidism received chemoradiation while rest 21 received radiotherapy alone. Mean period for developing radiation induced hypothyroidism was 4.5 months. Hypothyrodism (clinical or subclinical) is an under recognised morbidity of external radiation to the neck which is seen following a minimum dose of 30 Gy to the neck. Recognising hypothyroidism (clinical or subclinical) early and treating it prevents thyroid dysfunction related complications. Hence, thyroid function tests should be made routine during follow up in all patients undergoing radiotherapy.
头颈癌是印度最常见的恶性肿瘤之一。大多数头颈恶性肿瘤病例接受了有或没有手术的放化疗。无论是切除甲状腺还是甲状腺受到照射并纤维化,甲状腺都首当其冲。在这两种情况下,甲状腺功能都会丧失,导致甲状腺功能减退和其他临床表现。它往往处于亚临床状态,未被注意到。目的是确定接受颈部放疗的头颈癌患者中临床和亚临床甲状腺功能减退的发生率,并证明在随访期间常规进行甲状腺功能检查的合理性。这是一项对100名头颈癌患者进行的前瞻性非随机对照研究,这些患者接受了为期1年的放射治疗。在基线以及放疗后3个月和9个月时进行促甲状腺激素以及T3和T4的测定。100名患者中,72名(72%)为男性,28名(28%)为女性。所有患者颈部接受的辐射剂量均>30 Gy。35名患者接受了同步化疗。11名患者被发现有亚临床甲状腺功能减退,32名患者出现了明显的临床甲状腺功能减退(P值为0.001)。因此,共有43名患者发生了放射性甲状腺功能减退。32名发生临床甲状腺功能减退的患者中有20名年龄在41 - 50岁之间。32名发生临床甲状腺功能减退的患者中有11名接受了放化疗,其余21名仅接受了放疗。发生放射性甲状腺功能减退的平均时间为4.5个月。甲状腺功能减退(临床或亚临床)是颈部外照射未被充分认识的一种发病率,在颈部接受至少30 Gy的辐射后可见。早期识别并治疗甲状腺功能减退(临床或亚临床)可预防与甲状腺功能障碍相关的并发症。因此,在所有接受放疗的患者随访期间,应将甲状腺功能检查作为常规检查。